Background: Previous work has demonstrated that a partial normalization of the conformation of albumin from uraemic plasma and a substantial restoration of its binding abilities can be achieved by extraction with activated charcoal. This is best achieved at pH 3, but exposure of whole plasma to this low pH leads to the loss of some essential components. Methods: The melting curves and ligand-binding abilities of uraemic albumin have been investigated after extraction with a new generation of activated carbon at three pH values (7.2, 3.0 and 5.08). Results: Albumin isolated from uraemic plasma had a characteristically increased melting temperature because of bound ligands. Extraction of uraemic plasma at pH 7.2, 5.08 and 3.0 induced low-temperature shifts of albumin thermo-adsorption maximum T1 of 1.4, 3.8, 2.4°C and T2 of 0.8, 3.9 and 1.2°C, respectively. Flow microcalorimetry data demonstrated a decrease in the ability of uraemic albumin to bind octanoate, phenol red, salicylic acid, warfarin and diazepam. Purification of uraemic plasma at pH 5.08 completely restored the binding affinity of albumin for all the marker ligands. Conclusions: Highly efficient activated carbons, with clinically feasible acidification of plasma, can remove strongly albumin-bound uraemic toxins. Investigation of the melting curve of the isolated albumin is a new biophysical way to monitor both its molecular condition and the extent of removal of protein-bound toxins by dialysis. The melting curve provides new qualitative and quantitative information about albumin in an analogous way to an electrocardiogram and the heart.

Keywords:
Uraemia, Human albumin, Activated carbon, Melting curve
1.
Depner TA: Uremic toxicity: Urea and beyond. Semin Dial 2001;14:246–251.
2.
Sarnatskaya VV, Ivanov AI, Nikolaev VG, Rotellar E, von Appen K, Haspar M, Maslenny VN, Klinkmann H: Structure and binding properties of serum albumin in uremic patients at different periods of hemodialysis. Artif Organs 1998;22:107–115.
3.
Costigan MG, Yaqoob M, Lindup WE: Retention of an albumin-bound furan dicarboxylic acid in patients with chronic renal failure or after a kidney transplant. Nephrol Dial Transplant 1996;11:803–807.
4.
Nikolaev V, Sarnatskaya V, von Appen K, Ivanov A, Rotellar E, Haspar M, Klinkmann H: Biophysical studies on the correction of uremic human serum albumin binding defects by in vitro charcoal adsorption treatment. Artif Organs 1996;20:17–23.
5.
Port FK: Morbidity and mortality in dialysis patients. Kidney Int 1994;46:1728–1737.
6.
Bowmer CJ, Lindup WE: Binding of phenytoin, L-tryptophan and o-methyl red to albumin. Unexpected effect of albumin concentration on the binding of phenytoin and L-tryptophan. Biochem Pharmacol 1978;27:937–942.
7.
Gulyassy PF, Jarrard E, Stanfel LA: Contributions of hippurate, indoxyl sulfate and o-hydroxyhippurate to impaired ligand binding by plasma in azotemic humans. Biochem Pharmacol 1987;36:4215–4220.
8.
De Torrente A, Glazer GB, Gulyassy P: Reduced in vitro binding of tryptophan by plasma in uremia. Kidney Int 1974;6:222–229.
9.
Langsteger W: Diagnosis of thyroid hormone transport protein anomalies: An overview. Acta Med Austriaca 1996;23:31–40.
10.
Robertson A, Karp W, Brodersen R: Bilirubin displacing effect of drugs used in neonatology. Acta Paediatr Scand 1991;80:1119–1127.
11.
Costigan MG, Callaghan CA, Lindup WE: Hypothesis: is accumulation of a furan dicarboxylic acid (3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid) related to the neurological abnormalities in patients with renal failure? Nephron 1996;73:169–173.
12.
Lichtenwalner DM, Suh B, Lorber B, Rudnik MR, Craig WA: Correction of drug binding defects in uremia in vitro by anion exchange resin treatment. Biochem Pharmacol 1982;31:3483–3487.
13.
Chen RF: Removal of fatty acids from serum albumin by charcoal treatment. J Biol Chem 1967;242:173–181.
14.
Sjoholm I, Kober A, Odar-Cederlof I, Borga O: Protein binding of drugs in uremic and normal serum: The role of endogenous binding inhibitors. Biochem Pharmacol 1976;25:1205–1213.
15.
Craig WA, Evenson MA, Sarver KP, Wagnild JP: Correction of protein binding defect in uremic sera by charcoal treatment. J Lab Clin Med 1976;87:637–647.
16.
Depner TA, Gulyassy PF: Plasma protein binding in uremia: Extraction and characterization of an inhibitor. Kidney Int 1980;18:86–94.
17.
Lindup WE: Drug-plasma protein binding: Basic and clinical aspects; in Bridges JW, Chasseaud LF, Gibson GG (eds): Progress in Drug Metabolism. London, Taylor & Francis, 1987, pp 141–185.
18.
Sudharshan E, Srinivasulu S, Appu Rao AG: pH-induced domain interaction and conformational transition of lipoxygenase-1. Biochim Biophys Acta 2000;1480:13–22.
19.
Nikolaev VG, Sarnatskaya VV, Sigal VL, Klevtsov VN, Makhorin KE, Yushko LA: High-porosity activated carbons for bilirubin removal. Int J Artif Organs 1991;14:179–185.
20.
Nascimento MM, Pasqual DD, Dos Santos JE, Riella MC: Six years of treatment with the HELP system of a patient with familial hypercholesterolemia. Braz J Med Biol Res 2002;35:775–782.
21.
Vasileva R, Jakab M, Hasko F: Application of ion-exchange chromatography for the production of human albumin. J Chromatogr 1981;216:279–284.
22.
Mayer HR: Disk-Electrophorese. Berlin, de Gruyter, 1963.
23.
Privalov PL, Potekhin SA: Scanning microcalorimetry in studying temperature-induced changes in proteins. Methods Enzymol 1986;131:4–51.
24.
Coassolo P, Sarrazin M, Sari JS, Briand C: Microcalorimetric studies on the binding of some benzodiazepine derivatives to human serum albumin. Biochem Pharmacol 1978;27:2787–2792.
25.
Aki H, Yamamoto M: Thermodynamic characterization of drug binding to human serum albumin by isothermal titration microcalorimetry. J Pharm Sci 1994;83:1712–1716.
26.
Henderson SJ, Lindup WE: Interaction of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, an inhibitor of plasma protein binding in uraemia, with human albumin. Biochem Pharmacol 1990;40:2543–2548.
27.
Sarnatskaya VV, Lindup WE, Niwa T, Ivanov AI, Yushko LA, Tjia J, Maslenny VN, Korneeva LN, Nikolaev VG: Effect of protein-bound uraemic toxins on the thermodynamic characteristics of human albumin. Biochem Pharmacol 2002;63:1287–1296.
28.
Shrake A, Ross PD: Biphasic denaturation of human albumin due to ligand redistribution during unfolding. J Biol Chem 1988;263:15392–15399.
29.
Shrake A, Finlayson JS, Ross PD: Thermal stability of fatty acid-serum albumin complexes studied by differential scanning calorimetry. Biochim Biophys Acta 1979;574:189–196.
30.
Era S, Itoh KB, Sogami M, Kuwata K, Iwama T, Yamada H, Watari H: Structural transition. Int J Pept Protein Res 1990;35:1–11.
31.
Costigan MG, O’Callaghan CA, Lindup WE: Hypothesis: Is accumulation of a furan dicarboxylic acid (3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid) related to the neurological abnormalities in patients with renal failure? Nephron 1996;73:169–173.
32.
Costigan MG, Lindup WE: Plasma clearance in the rat of a furan dicarboxylic acid which accumulates in uremia. Kidney Int 1996;49:634–638.
33.
Mabuchi H, Nakahashi H: A major inhibitor of phenytoin binding to serum protein in uremia. Nephron 1988;48:310–314.
34.
Sakai T, Takadate A, Otagiri M: Characterization of binding site of uremic toxins on human serum albumin. Biol Pharm Bull 1995;18:1755–1761.
35.
Barker CE, Lindup WE: Effect of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid on the binding of fluorescent probes to human albumin. Br J Clin Pharmacol 1989;27:675P.
36.
Tsutsumi Y, Maruyama T, Takadate A, Goto M, Matsunaga H, Otagiri M: Interaction between two dicarboxylate endogenous substances, bilirubin and an uremic toxin, 3- carboxy-4-methyl-5-propyl-2-furanpropanoic acid, on human serum albumin. Pharm Res 1999;16:916–923.
37.
Vanholder R, De Smet R, Lameire N: Protein-bound uremic solutes: The forgotten toxins. Kidney Int 2001;59(suppl 78):266–270.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.